Compare NMM & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | AAPG |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Greece | China |
| Employees | N/A | 767 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2007 | N/A |
| Metric | NMM | AAPG |
|---|---|---|
| Price | $81.35 | $17.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $85.00 | $48.40 |
| AVG Volume (30 Days) | ★ 93.1K | 4.8K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | $290.34 |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.66 | $16.36 |
| 52 Week High | $80.97 | $48.45 |
| Indicator | NMM | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 40.91 |
| Support Level | $69.21 | $16.64 |
| Resistance Level | $80.69 | $18.17 |
| Average True Range (ATR) | 2.50 | 0.41 |
| MACD | 0.53 | -0.16 |
| Stochastic Oscillator | 79.97 | 3.83 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.